Skytrofa (lonapegsomatropin-tcgd) is a prescription drug that’s used to treat growth hormone deficiency (GHD) in certain children. It’s given by injection under the skin once weekly. Skytrofa is a ...
The approval was based on data from the phase 3 heiGHt trial, which compared Skytrofa to somatropin in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. Skytrofa ® ...
COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment ...
The approval was based on data from the phase 3 heiGHt trial that assessed Skytrofa in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. The Food and Drug Administration has ...
Ascendis Pharma announced that the US Food and Drug Administration (FDA) has approved Skytrofa (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11 ...
(RTTNews) - Ascendis Pharma A/S (ASND) reported that its second-quarter net loss widened from last year. In addition, the company said that the U.S. Food and Drug Administration approved its Skytrofa ...
SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[1] "We are delighted to have secured TGA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback